Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital

Fineline Cube Jul 3, 2024

Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...

Company Deals Medical Device

Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor

Fineline Cube Jul 3, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Drug

China’s Jiangsu Hengrui First to Market Generic Exparel in the US with FDA ANDA Approval

Fineline Cube Jul 3, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Shanghai Henlius Biotech Advances Serplulimab Phase III Trial for First-Line Metastatic Colorectal Cancer

Fineline Cube Jul 3, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...

Company Drug

MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru

Fineline Cube Jul 3, 2024

MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...

Company Drug

Legend Biotech’s Carvykti Shows Significant Overall Survival Improvement in Phase III CARTITUDE-4 Study

Fineline Cube Jul 3, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has announced positive results from the CARTITUDE-4 study, a global,...

Company Drug

Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval

Fineline Cube Jul 3, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration...

Company Drug

Johnson & Johnson’s Talvey Gets Green Light in South Korea for Multiple Myeloma

Fineline Cube Jul 3, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that its subsidiary Janssen Korea has received...

Company Policy / Regulatory

LEK Consulting’s Survey Reveals Biosecure Act’s Impact on Life Sciences Companies

Fineline Cube Jul 3, 2024

LEK Consulting, a UK/US firm, has published the results of a global survey aimed at...

Company Deals

Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin

Fineline Cube Jul 2, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its...

Company Drug

Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals

Fineline Cube Jul 2, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...

Company Drug

Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug

Fineline Cube Jul 2, 2024

Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for...

Company Drug

Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure

Fineline Cube Jul 2, 2024

Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its...

Company Policy / Regulatory

US Forms ‘Bio-5’ Coalition with Global Powers to Reduce Reliance on Chinese APIs

Fineline Cube Jul 2, 2024

The White House announced last week a suite of new initiatives aimed at bolstering domestic...

Company Deals Medical Device

Cryofocus Medtech Partners with Boston Scientific for Respiratory Products Distribution in China

Fineline Cube Jul 2, 2024

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Deals

PW Medtech Group Ltd Plans Independent Listing of Rekind Medtec on NEEQ to Boost Growth

Fineline Cube Jul 2, 2024

PW Medtech Group Ltd (HKG: 1358), a prominent medical device manufacturer based in China, is...

Company Drug

Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024

Fineline Cube Jul 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Medical Device

Ningbo-Based Jenscare Scientific Announces Successful Follow-up Data for Transjugular Tricuspid Valve Device

Fineline Cube Jul 2, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading manufacturer of structural heart disease devices headquartered...

Company Drug

Yantai Dongcheng Pharmaceutical’s 177LuLNC1011 Gets FDA Green Light for Prostate Cancer Clinical Trial

Fineline Cube Jul 2, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Drug

SCG Cell Therapy Receives FDA Approval for HPV-Targeted SCG142 Clinical Trial

Fineline Cube Jul 2, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-headquartered biotechnology company with a presence in Shanghai, has...

Posts pagination

1 … 283 284 285 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.